Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 70.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 70.60% |
| Dec 31, 2025 | 3.83% |
| Sep 30, 2025 | -7.74% |
| Jun 30, 2025 | 39.61% |
| Mar 31, 2025 | 92.04% |
| Dec 31, 2024 | 54.66% |
| Sep 30, 2024 | 49.71% |
| Jun 30, 2024 | 59.94% |
| Mar 31, 2024 | 121.92% |
| Dec 31, 2023 | 61.84% |
| Sep 30, 2023 | 57.88% |
| Jun 30, 2023 | 32.35% |
| Mar 31, 2023 | 18.48% |
| Dec 31, 2022 | 48.28% |
| Sep 30, 2022 | 36.43% |
| Jun 30, 2022 | 23.04% |
| Mar 31, 2022 | 45.13% |
| Dec 31, 2021 | 62.31% |
| Sep 30, 2021 | 72.15% |
| Jun 30, 2021 | 74.17% |